- Drug Pipelines
- January 2024
- 60 Pages
Global
From €1366EUR$1,500USD£1,175GBP
- Report
- November 2023
- 30 Pages
Global
From €2504EUR$2,750USD£2,154GBP
- Report
- November 2023
- 30 Pages
Global
From €2960EUR$3,250USD£2,545GBP
- Report
- June 2023
- 200 Pages
Global
From €6830EUR$7,500USD£5,874GBP
- Report
- April 2023
- 240 Pages
Global
From €3187EUR$3,500USD£2,741GBP
- Report
- February 2023
- 164 Pages
Global
From €6830EUR$7,500USD£5,874GBP
- Report
- February 2023
- 82 Pages
Global
From €3597EUR$3,950USD£3,093GBP
- Report
- September 2022
- 30 Pages
Global
From €2504EUR$2,750USD£2,154GBP
- Report
- September 2022
- 30 Pages
Global
From €2960EUR$3,250USD£2,545GBP
- Report
- September 2022
- 70 Pages
Global
From €3597EUR$3,950USD£3,093GBP
- Report
- September 2022
- 135 Pages
Global
From €6830EUR$7,500USD£5,874GBP
- Report
- August 2022
- 30 Pages
Global
From €2960EUR$3,250USD£2,545GBP
- Report
- August 2022
- 30 Pages
Global
From €2960EUR$3,250USD£2,545GBP
- Report
- August 2022
- 155 Pages
Global
From €6830EUR$7,500USD£5,874GBP
- Report
- August 2022
- 161 Pages
Global
From €6830EUR$7,500USD£5,874GBP
- Report
- August 2022
- 90 Pages
Global
From €3597EUR$3,950USD£3,093GBP
- Report
- August 2022
- 80 Pages
Global
From €3597EUR$3,950USD£3,093GBP
- Report
- June 2022
- 95 Pages
Global
From €3597EUR$3,950USD£3,093GBP
- Drug Pipelines
- March 2022
- 62 Pages
Global
From €3597EUR$3,950USD£3,093GBP
- Report
- January 2022
- 60 Pages
Global
From €3597EUR$3,950USD£3,093GBP

The Respiratory Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs used to treat respiratory diseases. These drugs are used to treat a variety of conditions, including asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. Commonly prescribed respiratory drugs include bronchodilators, corticosteroids, and antibiotics.
The Respiratory Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Companies in the market include GlaxoSmithKline, AstraZeneca, Merck & Co., Novartis, and Boehringer Ingelheim. These companies are constantly researching and developing new drugs to treat respiratory diseases, as well as improving existing treatments. Show Less Read more